{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:58:09Z","timestamp":1788562689038,"version":"build-2803163510"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY"},{"name":"Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY"},{"name":"Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY"},{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY"},{"name":"WCM Myeloma Center, Weill Cornell Medicine, New York, NY"},{"name":"Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"Meyer Cancer Center, Weill Cornell Medicine, New York, NY"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01390-5","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T18:45:06Z","timestamp":1776797106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["EXaCT-2: an augmented and customizable oncology-focused whole exome sequencing platform"],"prefix":"10.1038","volume":"10","author":[{"given":"Peter","family":"Waltman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken W.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Pabon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princesca","family":"Delpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavneet","family":"Bhinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi","family":"Manohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Gorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuele","family":"Simi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Zisimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majd","family":"Al Assaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Ten Eyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Demichelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu M.","family":"Ouseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Sigaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Rennert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Lindeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Miguel","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane C.","family":"Hassane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sigouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sboner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"1390_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrg.2017.89","volume":"19","author":"LA Hindorff","year":"2018","unstructured":"Hindorff, L. A. et al. Prioritizing diversity in human genomics research. Nat. Rev. Genet. 19, 175\u2013185 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"1390_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41591-021-01672-4","volume":"28","author":"S Fatumo","year":"2022","unstructured":"Fatumo, S. et al. A roadmap to increase diversity in genomic studies. Nat. Med. 28, 243\u2013250 (2022).","journal-title":"Nat. Med."},{"key":"1390_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-022-04601-8","volume":"604","author":"T Wang","year":"2022","unstructured":"Wang, T. et al. The Human Pangenome Project: a global resource to map genomic diversity. Nature 604, 437\u2013446 (2022).","journal-title":"Nature"},{"key":"1390_CR4","first-page":"56","volume":"3","author":"H Fang","year":"2022","unstructured":"Fang, H. et al. Tumour mutational burden is overestimated by target cancer gene panels. J. Natl. Cancer Cent. 3, 56\u201364 (2022).","journal-title":"J. Natl. Cancer Cent."},{"key":"1390_CR5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"1390_CR6","doi-asserted-by":"publisher","first-page":"700568","DOI":"10.3389\/fonc.2021.700568","volume":"11","author":"L Harbers","year":"2021","unstructured":"Harbers, L. et al. Somatic Copy Number Alterations in Human Cancers: An Analysis of Publicly Available Data From The Cancer Genome Atlas. Front. Oncol. 11, 700568 (2021).","journal-title":"Front. Oncol."},{"key":"1390_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1101\/gr.212225.116","volume":"27","author":"C Buccitelli","year":"2017","unstructured":"Buccitelli, C. et al. Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation. Genome Res. 27, 501\u2013511 (2017).","journal-title":"Genome Res"},{"key":"1390_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8399","volume":"355","author":"T Davoli","year":"2017","unstructured":"Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).","journal-title":"Science"},{"key":"1390_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor, A. M. et al. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33, 676\u2013689.e3 (2018).","journal-title":"Cancer Cell"},{"key":"1390_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1038\/s12276-024-01288-x","volume":"56","author":"R Kim","year":"2024","unstructured":"Kim, R. et al. Clinical application of whole-genome sequencing of solid tumors for precision oncology. Exp. Mol. Med. 56, 1856\u201368 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1390_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). J. Mol. Diagn. JMD 17, 251\u2013264 (2015).","journal-title":"J. Mol. Diagn. JMD"},{"key":"1390_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jamaoncol.2015.1313","volume":"1","author":"H Beltran","year":"2015","unstructured":"Beltran, H. et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 1, 466\u2013474 (2015).","journal-title":"JAMA Oncol."},{"key":"1390_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/npjgenmed.2016.19","volume":"1","author":"H Rennert","year":"2016","unstructured":"Rennert, H. et al. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. NPJ Genom. Med. 1, 16019 (2016).","journal-title":"NPJ Genom. Med"},{"key":"1390_CR14","unstructured":"Agilent Technologies. SureSelect Human All Exon V6. https:\/\/www.agilent.com\/cs\/library\/datasheets\/public\/SureSelect%20V6%20DataSheet%205991-5572EN.pdf (2015)."},{"key":"1390_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01470-y","volume":"8","author":"H-T Shin","year":"2017","unstructured":"Shin, H.-T. et al. Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nat. Commun. 8, 1377 (2017).","journal-title":"Nat. Commun."},{"key":"1390_CR16","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLOS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLOS Comput. Biol."},{"key":"1390_CR17","doi-asserted-by":"crossref","unstructured":"FusionGDB 2.0: fusion gene annotation updates aided by deep learning | Nucleic Acids Research | Oxford Academic. https:\/\/academic.oup.com\/nar\/article\/50\/D1\/D1221\/6424754.","DOI":"10.1093\/nar\/gkab1056"},{"key":"1390_CR18","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1158\/1078-0432.CCR-11-0034","volume":"17","author":"C Hawkins","year":"2011","unstructured":"Hawkins, C. et al. BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma. Clin. Cancer Res. 17, 4790\u20134798 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1390_CR19","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333\u2013i339 (2012).","journal-title":"Bioinformatics"},{"key":"1390_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41586-019-0879-y","volume":"566","author":"B Briney","year":"2019","unstructured":"Briney, B., Inderbitzin, A., Joyce, C. & Burton, D. R. Commonality despite exceptional diversity in the baseline human antibody repertoire. Nature 566, 393\u2013397 (2019).","journal-title":"Nature"},{"key":"1390_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-0337-y","volume":"10","author":"A Dogan","year":"2020","unstructured":"Dogan, A. et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J 10, 1\u201313 (2020).","journal-title":"Blood Cancer J"},{"key":"1390_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"1390_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1620\/tjem.156.319","volume":"156","author":"Y Nozawa","year":"1988","unstructured":"Nozawa, Y. et al. Establishment and characterization of an Epstein-Barr virus negative B-cell lymphoma cell line and successful heterotransplantation. Tohoku J. Exp. Med. 156, 319\u2013330 (1988).","journal-title":"Tohoku J. Exp. Med."},{"key":"1390_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/1097-0142(19880201)61:3<483::AID-CNCR2820610313>3.0.CO;2-L","volume":"61","author":"M Abe","year":"1988","unstructured":"Abe, M., Nozawa, Y., Wakasa, H., Ohno, H. & Fukuhara, S. Characterization and comparison of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability. Cancer 61, 483\u2013490 (1988).","journal-title":"Cancer"},{"key":"1390_CR25","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The Frequency of Ras Mutations in Cancer. Cancer Res. 80, 2969\u20132974 (2020).","journal-title":"Cancer Res"},{"key":"1390_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"1390_CR27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"AACR The","year":"2017","unstructured":"The, A. A. C. R. et al. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 7, 818\u2013831 (2017).","journal-title":"Cancer Discov."},{"key":"1390_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","volume":"12","author":"MH Hofmann","year":"2022","unstructured":"Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M. & Kraut, N. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov. 12, 924\u2013937 (2022).","journal-title":"Cancer Discov."},{"key":"1390_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42010-1","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu, D. et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat. Commun. 14, 6389 (2023).","journal-title":"Nat. Commun."},{"key":"1390_CR30","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig, M. N., Ashwood, L. M., Kondrashova, O. & Sutherland, K. D. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer 9, 955\u2013967 (2023).","journal-title":"Trends Cancer"},{"key":"1390_CR31","doi-asserted-by":"publisher","first-page":"1252516","DOI":"10.3389\/fonc.2023.1252516","volume":"13","author":"L Qunaj","year":"2023","unstructured":"Qunaj, L., May, M. S., Neugut, A. I. & Herzberg, B. O. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer. Front. Oncol. 13, 1252516 (2023).","journal-title":"Front. Oncol."},{"key":"1390_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.25","volume":"3","author":"JM Zook","year":"2016","unstructured":"Zook, J. M. et al. Extensive sequencing of seven human genomes to characterize benchmark reference materials. Sci. Data 3, 160025 (2016).","journal-title":"Sci. Data"},{"key":"1390_CR33","doi-asserted-by":"publisher","first-page":"D1243","DOI":"10.1093\/nar\/gkae974","volume":"53","author":"G Perez","year":"2025","unstructured":"Perez, G. et al. The UCSC Genome Browser database: 2025 update. Nucleic Acids Res. 53, D1243\u2013D1249 (2025).","journal-title":"Nucleic Acids Res"},{"key":"1390_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","volume":"158","author":"KA Hoadley","year":"2014","unstructured":"Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929\u2013944 (2014).","journal-title":"Cell"},{"key":"1390_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3376-4","volume":"17","author":"S Baechmann","year":"2017","unstructured":"Baechmann, S. et al. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. BMC Cancer 17, 374 (2017).","journal-title":"BMC Cancer"},{"key":"1390_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","volume":"48","author":"J Luo","year":"2021","unstructured":"Luo, J. KRAS mutation in Pancreatic Cancer. Semin. Oncol. 48, 10\u201318 (2021).","journal-title":"Semin. Oncol."},{"key":"1390_CR37","doi-asserted-by":"publisher","first-page":"799","DOI":"10.32604\/or.2024.045356","volume":"32","author":"S Stickler","year":"2024","unstructured":"Stickler, S., Rath, B. & Hamilton, G. Targeting KRAS in pancreatic cancer. Oncol. Res. 32, 799\u2013805 (2024).","journal-title":"Oncol. Res."},{"key":"1390_CR38","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3390\/jcm13072103","volume":"13","author":"F Nusrat","year":"2024","unstructured":"Nusrat, F. et al. The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma. J. Clin. Med. 13, 2103 (2024).","journal-title":"J. Clin. Med."},{"key":"1390_CR39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1525-1578(10)60571-5","volume":"7","author":"S Ogino","year":"2005","unstructured":"Ogino, S. et al. Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing. J. Mol. Diagn. JMD 7, 413\u2013421 (2005).","journal-title":"J. Mol. Diagn. JMD"},{"key":"1390_CR40","doi-asserted-by":"publisher","first-page":"e1007108","DOI":"10.1371\/journal.pgen.1007108","volume":"14","author":"RA Risques","year":"2018","unstructured":"Risques, R. A. & Kennedy, S. R. Aging and the rise of somatic cancer-associated mutations in normal tissues. PLoS Genet. 14, e1007108 (2018).","journal-title":"PLoS Genet"},{"key":"1390_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0648-4","volume":"11","author":"I Martincorena","year":"2019","unstructured":"Martincorena, I. Somatic mutation and clonal expansions in human tissues. Genome Med. 11, 35 (2019).","journal-title":"Genome Med"},{"key":"1390_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tig.2011.03.002","volume":"27","author":"S De","year":"2011","unstructured":"De, S. Somatic mosaicism in healthy human tissues. Trends Genet 27, 217\u2013223 (2011).","journal-title":"Trends Genet"},{"key":"1390_CR43","doi-asserted-by":"publisher","unstructured":"Krimmel, J. D., Salk, J. J. & Risques, R. A. Cancer-like mutations in non-cancer tissue: towards a better understanding of multistep carcinogenesis. Transl. Cancer Res. 5, https:\/\/doi.org\/10.21037\/tcr.2016.11.67 (2016).","DOI":"10.21037\/tcr.2016.11.67"},{"key":"1390_CR44","doi-asserted-by":"publisher","first-page":"viii650","DOI":"10.1093\/annonc\/mdy303.005","volume":"29","author":"ME Salem","year":"2018","unstructured":"Salem, M. E. et al. Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate\/low. Ann. Oncol. 29, viii650\u2013viii651 (2018).","journal-title":"Ann. Oncol."},{"key":"1390_CR45","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/2326-6066.CIR-19-0149","volume":"7","author":"AM Goodman","year":"2019","unstructured":"Goodman, A. M., Sokol, E. S., Frampton, G. M., Lippman, S. M. & Kurzrock, R. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol. Res. 7, 1570\u20131573 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1390_CR46","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jmoldx.2022.01.006","volume":"24","author":"S Kadri","year":"2022","unstructured":"Kadri, S., Sboner, A., Sigaras, A. & Roy, S. Containers in Bioinformatics: Applications, Practical Considerations, and Best Practices in Molecular Pathology. J. Mol. Diagn. 24, 442\u2013454 (2022).","journal-title":"J. Mol. Diagn."},{"key":"1390_CR47","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P Di Tommaso","year":"2017","unstructured":"Di Tommaso, P. et al. Nextflow enables reproducible computational workflows. Nat. Biotechnol. 35, 316\u2013319 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1390_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2017.11.003","volume":"20","author":"S Roy","year":"2018","unstructured":"Roy, S. et al. Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular Pathology and the College of American Pathologists. J. Mol. Diagn. 20, 4\u201327 (2018).","journal-title":"J. Mol. Diagn."},{"key":"1390_CR49","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jmoldx.2025.04.008","volume":"27","author":"S Kadri","year":"2025","unstructured":"Kadri, S. et al. Clinical Bioinformatician Body of Knowledge\u2014Bioinformatics and Software Core: A Report of the Association for Molecular Pathology. J. Mol. Diagn. 27, 566\u2013582 (2025).","journal-title":"J. Mol. Diagn."},{"key":"1390_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01543-4","volume":"17","author":"K Lavrichenko","year":"2025","unstructured":"Lavrichenko, K. et al. Recommendations for bioinformatics in clinical practice. Genome Med. 17, 124 (2025).","journal-title":"Genome Med"},{"key":"1390_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-024-11196-z","volume":"26","author":"V Belova","year":"2025","unstructured":"Belova, V. et al. Comparative evaluation of four exome enrichment solutions in 2024: Agilent, Roche, Vazyme and Nanodigmbio. BMC Genomics 26, 76 (2025).","journal-title":"BMC Genomics"},{"key":"1390_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-024-01767-7","volume":"9","author":"R Hosea","year":"2024","unstructured":"Hosea, R., Hillary, S., Naqvi, S., Wu, S. & Kasim, V. The two sides of chromosomal instability: drivers and brakes in cancer. Signal Transduct. Target. Ther. 9, 75 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1390_CR53","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41588-025-02233-y","volume":"57","author":"JS Thompson","year":"2025","unstructured":"Thompson, J. S. et al. Predicting resistance to chemotherapy using chromosomal instability signatures. Nat. Genet. 57, 1708\u20131717 (2025).","journal-title":"Nat. Genet."},{"key":"1390_CR54","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1470-2045(23)00241-3","volume":"24","author":"R Nocini","year":"2023","unstructured":"Nocini, R. et al. ICGC ARGO precision medicine: genomic profiling-informed prediction of immunotherapy response in two patients with metastatic head and neck squamous cell carcinoma. Lancet Oncol. 24, 851\u2013853 (2023).","journal-title":"Lancet Oncol."},{"key":"1390_CR55","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMsr1809937","volume":"381","author":"The All of Us Research Program Investigators","year":"2019","unstructured":"The All of Us Research Program Investigators The \u201cAll of Us\u201d Research Program. N. Engl. J. Med. 381, 668\u2013676 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1390_CR56","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1126\/science.1251546","volume":"344","author":"H3Africa Consortium","year":"2014","unstructured":"H3Africa Consortium et al. Research capacity. Enabling the genomic revolution in Africa. Science 344, 1346\u20131348 (2014).","journal-title":"Science"},{"key":"1390_CR57","first-page":"103521","volume":"0","author":"Y He","year":"2025","unstructured":"He, Y. et al. Longitudinal genomic analysis of five cases of recurrent thymomas. J. Thorac. Oncol. 0, 103521 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"1390_CR58","doi-asserted-by":"publisher","first-page":"110639","DOI":"10.1016\/j.celrep.2022.110639","volume":"39","author":"NK Altorki","year":"2022","unstructured":"Altorki, N. K. et al. Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma. Cell Rep. 39, 110639 (2022).","journal-title":"Cell Rep."},{"key":"1390_CR59","doi-asserted-by":"publisher","unstructured":"Kuo, H.-H. et al. Pan-Cancer PDOs Preserve Tumor Heterogeneity and Uncover Therapeutic Vulnerabilities. 2025.04.10.647635 Preprint at https:\/\/doi.org\/10.1101\/2025.04.10.647635 (2025).","DOI":"10.1101\/2025.04.10.647635"},{"key":"1390_CR60","doi-asserted-by":"publisher","first-page":"640","DOI":"10.21037\/atm.2019.10.116","volume":"7","author":"H-X Wu","year":"2019","unstructured":"Wu, H.-X. et al. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann. Transl. Med. 7, 640 (2019).","journal-title":"Ann. Transl. Med."},{"key":"1390_CR61","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha, D. et al. Tumor Mutational Burden (TMB) as a Predictive Biomarker in Solid Tumors. Cancer Discov. 10, 1808\u20131825 (2020).","journal-title":"Cancer Discov."},{"key":"1390_CR62","doi-asserted-by":"publisher","first-page":"706652","DOI":"10.3389\/fonc.2021.706652","volume":"11","author":"T Huang","year":"2021","unstructured":"Huang, T. et al. Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Oncol. 11, 706652 (2021).","journal-title":"Front. Oncol."},{"key":"1390_CR63","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2023-182291","volume":"142","author":"R Griffin","year":"2023","unstructured":"Griffin, R. et al. Tumor Mutational Burden As a Prognostic Factor in Diffuse Large B-Cell Lymphoma. Blood 142, 1633 (2023).","journal-title":"Blood"},{"key":"1390_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-1091-8","volume":"20","author":"K Li","year":"2020","unstructured":"Li, K., Luo, H., Huang, L., Luo, H. & Zhu, X. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 20, 16 (2020).","journal-title":"Cancer Cell Int"},{"key":"1390_CR65","first-page":"e15","volume":"26","author":"L Chang","year":"2018","unstructured":"Chang, L., Chang, M., Chang, H. M. & Chang, F. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. Appl. Immunohistochem. Mol. Morphol. AIMM 26, e15\u2013e21 (2018).","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"1390_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41177-2","volume":"9","author":"T Morihiro","year":"2019","unstructured":"Morihiro, T. et al. PD-L1 expression combined with microsatellite instability\/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Sci. Rep. 9, 4633 (2019).","journal-title":"Sci. Rep."},{"key":"1390_CR67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00384-023-04480-z","volume":"38","author":"P Rantanen","year":"2023","unstructured":"Rantanen, P. et al. The prognostic significance of microsatellite instability in colorectal cancer: a Swedish multi-center study. Int. J. Colorectal Dis. 38, 197 (2023).","journal-title":"Int. J. Colorectal Dis."},{"key":"1390_CR68","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"1390_CR69","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia, J. et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645\u2013651 (2018).","journal-title":"Nat. Genet."},{"key":"1390_CR70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","volume":"7","author":"L Fancello","year":"2019","unstructured":"Fancello, L., Gandini, S., Pelicci, P. G. & Mazzarella, L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J. Immunother. Cancer 7, 183 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1390_CR71","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmoldx.2024.05.002","volume":"26","author":"LV Furtado","year":"2024","unstructured":"Furtado, L. V. et al. Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer. J. Mol. Diagn. 26, 653\u2013668 (2024).","journal-title":"J. Mol. Diagn."},{"key":"1390_CR72","first-page":"PO.18.00400","volume":"3","author":"EM Fernandez","year":"2019","unstructured":"Fernandez, E. M. et al. Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO Precis. Oncol. 3, PO.18.00400 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"1390_CR73","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jmoldx.2022.01.008","volume":"24","author":"B Wei","year":"2022","unstructured":"Wei, B. et al. Evaluation of the TruSight Oncology 500 Assay for Routine Clinical Testing of Tumor Mutational Burden and Clinical Utility for Predicting Response to Pembrolizumab. J. Mol. Diagn. JMD 24, 600\u2013608 (2022).","journal-title":"J. Mol. Diagn. JMD"},{"key":"1390_CR74","doi-asserted-by":"publisher","first-page":"100944","DOI":"10.1016\/j.tranon.2020.100944","volume":"14","author":"S Beg","year":"2021","unstructured":"Beg, S. et al. Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. Transl. Oncol. 14, 100944 (2021).","journal-title":"Transl. Oncol."},{"key":"1390_CR75","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1390_CR76","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","volume":"18","author":"Z Sondka","year":"2018","unstructured":"Sondka, Z. et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696\u2013705 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1390_CR77","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 47, D941\u2013D947 (2019).","journal-title":"Nucleic Acids Res"},{"key":"1390_CR78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11523-013-0263-z","volume":"8","author":"D Planchard","year":"2013","unstructured":"Planchard, D. Identification of driver mutations in lung cancer: first step in personalized cancer. Target. Oncol. 8, 3\u201314 (2013).","journal-title":"Target. Oncol."},{"key":"1390_CR79","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung, K. L. et al. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin. Cancer Res: J. Am. Assoc. Cancer Res. 24, 1344\u20131354 (2018).","journal-title":"Clin. Cancer Res: J. Am. Assoc. Cancer Res."},{"key":"1390_CR80","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-22-3089","volume":"29","author":"BL Ecker","year":"2023","unstructured":"Ecker, B. L. et al. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res: J. Am. Assoc. Cancer Res. 29, 1368\u20131374 (2023).","journal-title":"Clin. Cancer Res: J. Am. Assoc. Cancer Res."},{"key":"1390_CR81","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/jnci\/djaa044","volume":"112","author":"SX Zhang","year":"2020","unstructured":"Zhang, S. X., Fergusson, D. & Kimmelman, J. Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved. JNCI J. Natl. Cancer Inst. 112, 886\u2013892 (2020).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"1390_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-024-01402-7","volume":"17","author":"A Beg","year":"2024","unstructured":"Beg, A., Parveen, R., Fouad, H., Yahia, M. E. & Hassanein, A. S. Unravelling driver genes as potential therapeutic targets in ovarian cancer via integrated bioinformatics approach. J. Ovarian Res. 17, 86 (2024).","journal-title":"J. Ovarian Res."},{"key":"1390_CR83","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","volume":"177","author":"G Sirugo","year":"2019","unstructured":"Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic Studies. Cell 177, 26\u201331 (2019).","journal-title":"Cell"},{"key":"1390_CR84","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s42003-023-05708-y","volume":"7","author":"E Venner","year":"2024","unstructured":"Venner, E. et al. The frequency of pathogenic variation in the All of Us cohort reveals ancestry-driven disparities. Commun. Biol. 7, 174 (2024).","journal-title":"Commun. Biol."},{"key":"1390_CR85","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1200\/JCO.2024.42.16_suppl.5017","volume":"42","author":"LF Valle","year":"2024","unstructured":"Valle, L. F. et al. Oncogenic alteration rates, race, and prostate cancer specific mortality in Veterans with metastatic prostate cancer undergoing somatic tumor next generation sequencing. J. Clin. Oncol. 42, 5017\u20135017 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1390_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq072","volume":"38","author":"M Mokry","year":"2010","unstructured":"Mokry, M. et al. Accurate SNP and mutation detection by targeted custom microarray-based genomic enrichment of short-fragment sequencing libraries. Nucleic Acids Res. 38, e116 (2010).","journal-title":"Nucleic Acids Res"},{"key":"1390_CR87","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1093\/nar\/gkn089","volume":"36","author":"F Demichelis","year":"2008","unstructured":"Demichelis, F. et al. SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res 36, 2446\u20132456 (2008).","journal-title":"Nucleic Acids Res"},{"key":"1390_CR88","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","volume":"6","author":"K Ellrott","year":"2018","unstructured":"Ellrott, K. et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 6, 271\u2013281.e7 (2018).","journal-title":"Cell Syst."},{"key":"1390_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0439-6","volume":"15","author":"D Prandi","year":"2014","unstructured":"Prandi, D. et al. Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 15, 439 (2014).","journal-title":"Genome Biol."},{"key":"1390_CR90","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","volume":"30","author":"B Niu","year":"2014","unstructured":"Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015\u20131016 (2014).","journal-title":"Bioinformatics"},{"key":"1390_CR91","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.gpb.2020.02.001","volume":"18","author":"P Jia","year":"2020","unstructured":"Jia, P. et al. MSIsensor-Pro: Fast, Accurate, and Matched-Normal-Sample-Free Detection of Microsatellite Instability. Genomics Proteom. Bioinforma. 18, 65\u201371 (2020).","journal-title":"Genomics Proteom. Bioinforma."},{"key":"1390_CR92","doi-asserted-by":"publisher","unstructured":"Stromberg, M. et al. Nirvana: Clinical Grade Variant Annotator. In Proceedings of the 8th ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics 596 (Association for Computing Machinery, New York, NY, USA, https:\/\/doi.org\/10.1145\/3107411.3108204 (2017).","DOI":"10.1145\/3107411.3108204"},{"key":"1390_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med"},{"key":"1390_CR94","doi-asserted-by":"publisher","unstructured":"Fernandez, E. M. et al. Cancer-Specific Thresholds Adjust for Whole Exome Sequencing\u2013Based Tumor Mutational Burden Distribution. JCO Precis. Oncol. 1\u201312 https:\/\/doi.org\/10.1200\/PO.18.00400 (2019).","DOI":"10.1200\/PO.18.00400"},{"key":"1390_CR95","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"1390_CR96","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576 (2012).","journal-title":"Genome Res"},{"key":"1390_CR97","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/bioinformatics\/btr665","volume":"28","author":"DE Larson","year":"2012","unstructured":"Larson, D. E. et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311\u2013317 (2012).","journal-title":"Bioinformatics"},{"key":"1390_CR98","doi-asserted-by":"publisher","unstructured":"Benjamin, D. et al. Calling Somatic SNVs and Indels with Mutect2. 861054 Preprint at https:\/\/doi.org\/10.1101\/861054 (2019).","DOI":"10.1101\/861054"},{"key":"1390_CR99","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"1390_CR100","doi-asserted-by":"publisher","first-page":"e111516","DOI":"10.1371\/journal.pone.0111516","volume":"9","author":"AJ Radenbaugh","year":"2014","unstructured":"Radenbaugh, A. J. et al. RADIA: RNA and DNA integrated analysis for somatic mutation detection. PloS One 9, e111516 (2014).","journal-title":"PloS One"},{"key":"1390_CR101","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-0716-2293-3_2","volume":"2493","author":"S Ji","year":"2022","unstructured":"Ji, S., Montierth, M. D. & Wang, W. MuSE: A Novel Approach to Mutation Calling with Sample-Specific Error Modeling. Methods Mol. Biol. Clifton NJ 2493, 21\u201327 (2022).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"1390_CR102","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","volume":"25","author":"K Ye","year":"2009","unstructured":"Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865\u20132871 (2009).","journal-title":"Bioinformatics"},{"key":"1390_CR103","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-021-03205-y","volume":"590","author":"D Taliun","year":"2021","unstructured":"Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 590, 290\u2013299 (2021).","journal-title":"Nature"},{"key":"1390_CR104","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 625, 92\u2013100 (2024).","journal-title":"Nature"},{"key":"1390_CR105","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium","year":"2020","unstructured":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020).","journal-title":"Nature"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01390-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01390-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:05:24Z","timestamp":1782173124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01390-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1390"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01390-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6612849\/v1","asserted-by":"object"}]},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Theresa Ten Eyck, Douglas Roberts, and Carlos Pabon are or were employees of Agilent Technologies, the maker\/producer of the EXaCT-2 assay. The other authors do not have a competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}